Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07436793 · ClinicalTrials.gov registry record · Phase 2
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT07436793: Recruiting Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
NCT07436793 is a Phase 2 study that is actively recruiting participants, run by New Mexico Cancer Research Alliance. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07436793, a Phase 2 study, is actively recruiting participants, sponsored by New Mexico Cancer Research Alliance.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.
Primary Outcome
Will be determined by a change in the percentage in the expression of the proliferative marker Ki-67 comparing the pretreatment diagnostic biopsy to the posttreatment hysterectomy specimen. Immunohistochemical evaluation of Ki-67 protein expression will be determined as a continuous variable using the percent of cells staining positive in the nucleus
Interventions
- PROCEDURE Biopsy Procedure
- DRUG Megestrol Acetate
- PROCEDURE Hysterectomy
- PROCEDURE Curettage Procedure
- DRUG Progesterone Only Hormone Replacement Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 2 |
What NCT07436793 shows while recruiting
NCT07436793 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Biopsy Procedure is the first listed.
NCT07436793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07436793 about?
NCT07436793 is a clinical study titled "Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial". This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approve...
What is the current status of trial NCT07436793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2026-06-15. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT07436793?
The interventions under investigation include: Biopsy Procedure (PROCEDURE), Megestrol Acetate (DRUG), Hysterectomy (PROCEDURE), Curettage Procedure (PROCEDURE), Progesterone Only Hormone Replacement Therapy (DRUG).
Who is sponsoring clinical trial NCT07436793?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07436793's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI